About Us | Contact Us |        

Maximizing Therapeutic Safety and Efficacy in IBD: A Treat-to-Target Approach

Gastroenterology
Curriculum:
Maximizing Therapeutic Safety and Efficacy in IBD: A Treat-to-Target Approach - Enduring
Credits:
1.5 AMA PRA Category 1 Credit(s)™
Launch Date:
July 28, 2015
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Physicians, physician assistants, and nurse practitioners

Relevant Terms:

Inflammatory bowel disease

Miguel Regueiro, MD, AGAF, FACG, FACP

Miguel Regueiro, MD, AGAF, FACG, FACP
Professor of Medicine
Professor, Clinical and Translational Science
University of Pittsburgh School of Medicine
Associate Chief for Education, Division of Gastroenterology, Hepatology,
and Nutrition
Head, Clinical Inflammatory Bowel Disease Program
Co-Director, Inflammatory Bowel Disease Center
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania

Dr. Miguel Regueiro earned his bachelor’s degree at the University of Pennsylvania and his medical degree at Hahnemann University in Philadelphia, Pennsylvania. He completed his internal medicine internship and residency and his clinical and research fellowship training in gastroenterology at Harvard Medical School’s Beth Israel Hospital in Boston, Massachusetts.
 
Dr. Regueiro is professor of medicine at the University of Pittsburgh School of Medicine, head of the Clinical Inflammatory Bowel Disease Program, and co-director of the Inflammatory Bowel Disease Center at the University of Pittsburgh Medical Center. He is also the associate chief for education and former director of the Gastroenterology, Hepatology, and Nutrition Fellowship Training Program at the University of Pittsburgh.
 
Dr. Regueiro’s main clinical and research interest is inflammatory bowel disease (IBD), with a focus on Crohn’s disease and ulcerative colitis. He has published extensively on the prevention and management of postoperative Crohn’s disease and genotype-phenotype correlations in IBD. He is the principal investigator on several multi-center, international research trials and conducts clinical research that defines the natural course and phenotypes of IBD. Dr. Regueiro has developed a multidisciplinary IBD center that operates as a state-of-the-art clinic for patients with Crohn’s disease and ulcerative colitis.
 
Dr. Regueiro has received several honors and holds membership in professional and scientific societies, including the Alpha Omega Alpha Honor Medical Society, the Joan Komblum Memorial Prize for Excellence in Internal Medicine, the Clinical Investigator Training Award from Harvard/MIT Health Sciences, the Crohn’s & Colitis Foundation of America (CCFA) Physician of the Year, the National Research Excellence in GI disease award, numerous fellowship teaching awards, and American Gastroenterological Association and American College of Gastroenterology Fellowships. He is also a member and fellow of the American Gastroenterological Association, the American College of Gastroenterology, and the American College of Physicians. He is a member of CCFA and co-chair of CCFA’s professional education committee. In addition, Dr. Regueiro has been an invited lecturer and keynote speaker for national and international seminars and has published many articles, reviews, and abstracts in peer-reviewed gastroenterology journals.

Gil Y. Melmed, MD, MS

Gil Y. Melmed, MD, MS
Director of Clinical Trials, Inflammatory Bowel Disease Center
Cedars-Sinai Medical Center
Associate Professor of Medicine
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, California

Dr. Gil Y. Melmed received his medical degree from Albert Einstein College of Medicine in New York, New York. He completed his residency at Cedars-Sinai Medical Center in Los Angeles, California, and his gastroenterology fellowship at University of California, Los Angeles, where he also received a master's of science in clinical research. He is board certified by the American Board of Internal Medicine in gastroenterology.
 
Dr. Melmed is director of clinical trials at the Clinical Inflammatory Bowel Disease (IBD) Center at Cedars-Sinai Medical Center and associate professor of medicine at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA). His main clinical and research interests are clinical outcomes in IBD (Crohn’s disease and ulcerative colitis), including health-related quality of life, post-operative outcomes, vaccination and health maintenance issues in patients with IBD, and quality of care for IBD. He has authored or co-authored over 70 publications and serves as a review editor for Inflammatory Bowel Disease. He is an active member of the Crohn’s & Colitis Foundation of America and co-chair of the national Quality of Care Committee.
1. Compare and contrast the clinical effects of IBD therapies
2. Select individualized treatments for patients with IBD that maximize the opportunity to achieve remission and avoid relapse while minimizing toxicity
3. Employ ongoing monitoring strategies assessing treatment goals and implement changes in treatment plans as appropriate
4. Utilize AGA practice measures for the management of IBD patients to slow the disease course and minimize complications

PHYSICIAN CONTINUING MEDICAL EDUCATION
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of The AGA Institute and RMEI, LLC. The AGA Institute is accredited by the ACCME to provide continuing medical education for physicians.
 
Credit Designation
The AGA Institute designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE OF CONFLICTS OF INTEREST
In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.
 
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
  • Miguel Regueiro, MD, AGAF, FACG, FACP, has affiliations with AbbVie, Janssen, UCB, Takeda, Shire (Consultant).
  • Gil Y. Melmed, MD, MS, has affiliations with AbbVie, Celgene, Genentech, Given Imaging, Janssen, Luitpold Pharmaceuticals, Pfizer, Prometheus Laboratories, Takeda, UCB (Consultant); Pfizer, Prometheus Laboratories (Research).
RMEI, LLC
  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests relative to the content to disclose.
  • Boris Rozenfeld, MD, has no affiliations with commercial interests to disclose.
  • Amy Reeve has no affiliations with commercial interests relative to the content to disclose.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
 
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 
Estimated time to complete: 1.5 hours
Medium: Internet

FEE INFORMATION
There is no fee for this educational activity.

STATEMENT OF SUPPORT
This activity is supported by independent educational grants from AbbVie Inc. and Prometheus Laboratories Inc.

HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians, physician assistants, and nurse practitioners are entitled to receive up to 1.5 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:
 
  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
Physicians, physician assistants, and nurse practitioners who successfully complete the post-test and evaluation will receive CME credit. Users must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation
 
COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above

For video playback, install the latest version of Flash or Quicktime.
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above